An Oxford University study found that early treatment with budesonide, a steroid used in asthma treatments, significantly reduced the need for urgent care and hospitalization in COVID-19 positive people. The study was funded by Oxford NIHR Biomedical Research Centre and AstraZeneca.
According to the National Health Service (NHS), the budesonide inhaler is called a “preventer” inhaler because it helps to prevent people from getting symptoms relating to asthma.
Budesonide is a prescription-only medicine and comes in the form of a nasal spray, tablets, capsules and granules or rectal foam and enemas. According to its instructions, budesonide inhaler may be used everyday, even if there are no symptoms. This medicine can be given to children 5 years and older.
The preprint server for health sciences conducted a randomised study using 146 patients. Early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced the recovery period, soon after falling sick with COVID-19.
There were fewer participants with persistent COVID-19 symptoms at 14 and 28 days after budesonide therapy vis-a-vis normal care.
Just like the study done on budesonide there have been studies done on other accessible and alternative medicines. At INN24 news, we did a story on how Vitamin D may be able to resist the COVID-19 virus because of how it regulates the immune system.
Watch the video below on more information about Vitamin D and how it helps your body to fight the COVID-19 virus.
⬡
Wiki Production Code: A0628
